Abstract
The aim was to measure the effective dose of flat-detector CT (FDCT) whole-brain imaging, biphasic FDCT angiography (FDCT-A), and FDCT perfusion (FDCT-P) protocols and compare it to previously reported effective dose values of multidetector CT (MDCT) applications. We measured effective dose according to the IRCP 103 using an anthropomorphic phantom equipped with thermoluminescent dosimeters (TLDs). Placement was according to anatomical positions of each organ. In total, 60 TLDs (≥ 4 TLDs/organ) were placed into and onto the phantom to account for all relevant organs. Organs within the primary beam were covered with more TLDs. Additionally, we measured dose to the eye lens with two TLDs per eye. Protocols which we routinely use in clinical practice were measured on a biplane angiography system. The effective dose of the 20-s protocol/7-s protocol for whole-brain imaging was 2.6mSv/2.4mSv. The radiation dose to the eye lens was 24/23mGy. For the biphasic high-/low-dose FDCT-A protocol, the effective dose was 8.9/2.8mSv respectively. The eye lens dose was 60/14mGy. The contribution of bolus tracking to the effective dose was 0.66mSv (assuming average duration of 14s). The multisweep FDCT-P protocol had an effective dose of 5.9mSv and an eye lens dose of 46mGy. Except for the high-dose biphasic FDCT-A protocol, FDCT applications used in neuroradiology have effective doses, which do not deviate more than 1mSv from previously reported values for MDCT applications. However, the effective dose to the eye lens in commonly used stroke paradigms exceeds the recommended annual dose twofold. • Flat-detector computed tomography (FDCT) can be used for acute and periinterventional imaging of acute stroke patients and in neurointerventions. • Except for the high-dose FDCT angiography protocol, the effective doses do not deviate more than 1mSv from previously reported values for multidetector CT applications. • Strategies to decrease the effective lens dose especially in younger patients should be evaluated in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
